⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE

Official Title: ADOPT-PRESTAGE: Randomized Controlled Trial on Acceptability, Diffusion and Impact on Treatment Adherence and Persistence of the PRESTAGE Program (Program for Education and Support for Oral Cancer Treatments in the Elderly) - Randomized Controlled Study Evaluating the Impact of the Program PRESTAGE

Study ID: NCT03296150

Interventions

PRESTAGE

Study Description

Brief Summary: As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes. Poor adherence affects particularly geriatric patients due among others to polypharmacy or cognitive impairment. Thus, the need for educational programs in this population has been regularly emphasized. PRESTAGE educational program was built after an external and internal analysis of educational needs in elderly patients treated with oral cancer treatments. It implicates a multidisciplinary educational team (nurses, physicians, pharmacists, psychologists, physiologists, social workers...). Six educational workshops were designed with the following endpoints: disease and treatment understanding, treatment management, nutrition and psychological as well as physical well being. ADOPT-PRESTAGE is a clinical, prospective, interventional, open-label, multicenter, randomized, controlled trial designed to evaluate the impact of PRESTAGE program. It is, to the investigators' knowledge, the first randomized controlled trial evaluating the acceptability and impact (adherence, clinical benefit) of an educational program in an elderly cancer population. The primary endpoint of this trial will be to evaluate adherence using an indirect objective adherence measure: the Medication Event Monitoring System (MEMS). Secondary endpoints include quality of life and evaluation of changes in patients' behaviors.

Detailed Description:

Eligibility

Minimum Age: 70 Years

Eligible Ages: OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Service de neuro-oncologie, Hôpital Pierre Wertheimer, HCL, Bron, , France

Service de Gériatrie, Centre Hospitalier de Givors, Givors, , France

Service d'oncologie médicale, Centre Hospitalier Universitaire de Grenbole, La Tronche, , France

Service de Médecine du vieillissement, Hôpital Edouard Herriot, HCL, Lyon, , France

Service de médecine du vieillissement, Hôpital de la Croix-Rousse, HCL, Lyon, , France

Service d'oncologie médicale, Cnetre Léon Bérard, Lyon, , France

Service d'oncologie, Centre Hospitalier Annecy Genevois, Metz-Tessy, , France

Service de Médecine du vieillissement, Centre Hospitalier Lyon Sud (Hospices Civils de Lyon), Pierre-Bénite, , France

service de gériatrie, Hôpital de la Charité, Centre Hospitalier Universitaire de St-Etienne, Saint-Étienne, , France

Contact Details

Name: Olivia LE SAUX

Affiliation: Hospices Civils de Lyon

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: